Scottie Resources Corp. (TSXV: SCOT) (OTCQB: SCTSF) (FSE: SR80) ("Scottie" or the "Company") is pleased to announce that ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad ...

TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced microRNA Clinical Programs GLASGOW, Scotland, March 19, 2026 (GLOBE NEWSWIRE) -- Causeway ...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed ...

AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Bre ...

Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...